Limits...
Recombinant PTH: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis.

McNeilly T, McNally C, Finch M, Beringer T - Ulster Med J (2013)

Bottom Line: At the time of analysis 60 patients had completed treatment, 53 patients were receiving ongoing treatment and 25 patients did not complete the 18 month course.On completion vertebral bone mineral density (BMD) had increased by 8.3% while femoral neck BMD had increased by 3.5%.Health outcome measures (EuroQoL-5 and patient visual analogue scale) indicated improvement in the quality of life of patients of those who completed the treatment course.

View Article: PubMed Central - PubMed

Affiliation: Osteoporosis Service, Belfast Health and Social Care Trust, Musgrave Park Hospital, Belfast BT9 7JB.

ABSTRACT

Introduction: Osteoporosis results in significant morbidity and mortality for a large number of patients within Northern Ireland. Recombinant PTH (Teriparatide) is one of a growing number of treatment options for the disease.

Methods: A retrospective analysis was carried out for all patients who had been commenced on Teriparatide since it was first used in the Belfast Health and Social Care Trust (BHSCT) in 2007. Patient demographics, clinical history and prior treatment were recorded prior to an eighteen month treatment protocol. Outcome measures including bone densitometry, bone turnover markers and health status were assessed on commencement and completion.

Results: 138 patients have commenced teriparatide therapy since 2007 (9 male, 129 female). At the time of analysis 60 patients had completed treatment, 53 patients were receiving ongoing treatment and 25 patients did not complete the 18 month course. On completion vertebral bone mineral density (BMD) had increased by 8.3% while femoral neck BMD had increased by 3.5%. Bone turnover markers demonstrated a significant increase of bone formation and resorption at 4 months, with a smaller increase at 18 months. Health outcome measures (EuroQoL-5 and patient visual analogue scale) indicated improvement in the quality of life of patients of those who completed the treatment course.

Conclusions: Experience in the BHSCT with teriparatide since 2007 demonstrates improvement in BMD comparable to published data, changes in bone turnover markers consistent with increased bone remodeling and better health outcomes for patients.

Show MeSH

Related in: MedlinePlus

Change in mea P1NP level over the duration of Teriparatide therapy
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3756865&req=5

fig03: Change in mea P1NP level over the duration of Teriparatide therapy

Mentions: At commencement the mean P1NP level for 122 patients was 35.7 ng/mL (SE - 2.34). At 4 months of treatment the mean P1NP was 117.3 ng/mL (SE - 7.52) for a total of 90 patients. On completion of the 18 month course the mean P1NP value was 81.5 ng/mL (SE - 7.58) for a total of 56 patients. (fig 3)


Recombinant PTH: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis.

McNeilly T, McNally C, Finch M, Beringer T - Ulster Med J (2013)

Change in mea P1NP level over the duration of Teriparatide therapy
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3756865&req=5

fig03: Change in mea P1NP level over the duration of Teriparatide therapy
Mentions: At commencement the mean P1NP level for 122 patients was 35.7 ng/mL (SE - 2.34). At 4 months of treatment the mean P1NP was 117.3 ng/mL (SE - 7.52) for a total of 90 patients. On completion of the 18 month course the mean P1NP value was 81.5 ng/mL (SE - 7.58) for a total of 56 patients. (fig 3)

Bottom Line: At the time of analysis 60 patients had completed treatment, 53 patients were receiving ongoing treatment and 25 patients did not complete the 18 month course.On completion vertebral bone mineral density (BMD) had increased by 8.3% while femoral neck BMD had increased by 3.5%.Health outcome measures (EuroQoL-5 and patient visual analogue scale) indicated improvement in the quality of life of patients of those who completed the treatment course.

View Article: PubMed Central - PubMed

Affiliation: Osteoporosis Service, Belfast Health and Social Care Trust, Musgrave Park Hospital, Belfast BT9 7JB.

ABSTRACT

Introduction: Osteoporosis results in significant morbidity and mortality for a large number of patients within Northern Ireland. Recombinant PTH (Teriparatide) is one of a growing number of treatment options for the disease.

Methods: A retrospective analysis was carried out for all patients who had been commenced on Teriparatide since it was first used in the Belfast Health and Social Care Trust (BHSCT) in 2007. Patient demographics, clinical history and prior treatment were recorded prior to an eighteen month treatment protocol. Outcome measures including bone densitometry, bone turnover markers and health status were assessed on commencement and completion.

Results: 138 patients have commenced teriparatide therapy since 2007 (9 male, 129 female). At the time of analysis 60 patients had completed treatment, 53 patients were receiving ongoing treatment and 25 patients did not complete the 18 month course. On completion vertebral bone mineral density (BMD) had increased by 8.3% while femoral neck BMD had increased by 3.5%. Bone turnover markers demonstrated a significant increase of bone formation and resorption at 4 months, with a smaller increase at 18 months. Health outcome measures (EuroQoL-5 and patient visual analogue scale) indicated improvement in the quality of life of patients of those who completed the treatment course.

Conclusions: Experience in the BHSCT with teriparatide since 2007 demonstrates improvement in BMD comparable to published data, changes in bone turnover markers consistent with increased bone remodeling and better health outcomes for patients.

Show MeSH
Related in: MedlinePlus